Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-04, Stock:LLY, The news for the past five days is as follows:
2018-05-25: NEWS1: Teva’s Fremanezumab Gets September Action Date from FDA.NEWS2: Barclays Raises Its 12-Month Target Price on Teva Stock.NEWS3: A Brief Overview of Merck’s First-Quarter Performance.NEWS4: Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval.NEWS5: Dow 30 Stock Roundup: GE's Transportation Unit to Merge With Wabtec, J&J & Glaxo's HIV Drug Gets EU Approval.
2018-05-29: NEWS1: Novo Nordisk's oral diabetes drug beats Jardiance in study.NEWS2: Analyzing Incyte’s Revenue Stream in Q1 2018.NEWS3: An Overview Merck’s Diabetes and Women’s Health Portfolios.NEWS4: Incyte’s Revenue Trend in Q1 2018.
2018-05-30: NEWS1: A Look at the Upside Potential of AstraZeneca Stock.NEWS2: Lilly to Participate in Jefferies Global Healthcare Conference.NEWS3: Allergan Recalls Taytulla Oral Contraceptives, Stock Down.NEWS4: Allergan Recalls Taytulla Oral Contraceptives, Stock Down.NEWS5: Top Analyst Reports for Chevron, Wells Fargo & Eli Lilly.NEWS6: Top Analyst Reports for Chevron, Wells Fargo & Eli Lilly.NEWS7: Top Analyst Reports for Chevron, Wells Fargo & Eli Lilly.NEWS8: Allergan Recalls Taytulla Oral Contraceptives, Stock Down.NEWS9: Novo Nordisk's Oral Ozempic Positive in Diabetes Study.NEWS10: Novo Nordisk's Oral Ozempic Positive in Diabetes Study.NEWS11: Novo Nordisk&apos;s Oral Ozempic Positive in Diabetes Study.NEWS12: A Look at Incyte’s Product Portfolio in May.
2018-05-31: NEWS1: Lilly to Participate in Goldman Sachs Global Healthcare Conference.NEWS2: How GlaxoSmithKline’s Segments Performed in Q1 2018.NEWS3: Top Diabetes Stocks to Buy Today.NEWS4: Top Diabetes Stocks to Buy Today.NEWS5: How Novartis’s Valuation Compares.NEWS6: Top Diabetes Stocks to Buy Today.NEWS7: The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero.NEWS8: The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero.NEWS9: 3 Biotechs With Huge FDA Decisions in June.NEWS10: 3 Biotechs With Huge FDA Decisions in June.NEWS11: The Zacks Analyst Blog Highlights: Chevron, Wells Fargo, Eli Lilly, FedEx and Valero.NEWS12: 3 Biotechs With Huge FDA Decisions in June.
2018-06-01: NEWS1: Lilly gets U.S. nod for arthritis drug, sets price well below rivals.NEWS2: FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis.NEWS3: FDA approves lower dose of Lilly-Incyte arthritis drug.NEWS4: A Closer Look at Novartis’s Innovative Medicine Business.NEWS5: Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis.NEWS6: Can Nektar Therapeutics Disrupt This $20 Billion Market?.NEWS7: Can Nektar Therapeutics Disrupt This $20 Billion Market?.

Answer: Rise